SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astec Lifesciences informs about outcome of board meeting

24 Jun 2025 Evaluate
Astec Lifesciences has informed that the Board of Directors of the Company (the Board), at its Meeting held today, on Tuesday, 24th June, 2025, has considered and approved the issue of fully paid-up Equity Shares of the Company of face value of Rs 10 each (the Equity Shares) for an amount not exceeding Rs. 250 Crore (Rupees Two Hundred and Fifty Crore) by way of a Rights Issue to the eligible Equity Shareholders of the Company as on the record date (to be determined and notified subsequently, and such issue, the Rights Issue), in accordance with applicable laws, including the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the SEBI ICDR Regulations), as amended, subject to such regulatory and statutory approvals, as may be relevant under the applicable laws. For the purposes of giving effect to the Rights Issue, the specific and detailed terms in relation to the Rights Issue, including but not limited to, the determination of the issue price, rights entitlement ratio, record date, timing of the rights issue and terms of payment will be determined by the Board and / or a duly constituted Committee of the Board of Directors authorized in this regard. The Meeting of the Board commenced at 10.00 a.m. and concluded at 11.25 am. This disclosure is made in terms of Regulation 30 read with Schedule III and other applicable provisions of the Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, as amended/updated from time to time.

The above information is a part of company’s filings submitted to BSE.

Astec Lifesciences Share Price

706.70 -0.30 (-0.04%)
07-May-2026 12:45 View Price Chart
Peers
Company Name CMP
UPL 660.05
PI Industries 3108.00
Bayer CropScience 4650.00
Sharda Cropchem 1135.00
Sumitomo Chemical 504.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×